Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | JUN | P05412 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.72 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.72 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.72 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.72 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.70 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.69 |
| ▸ | CTSB | P07858 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598357 | 1.00 | MAPT (1.00) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL10468808 | 0.92 | MAPT (0.85) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL11999773 | 0.92 | MAPT (0.85) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL10468807 | 0.92 | MAPT (0.85) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL29428462 | 0.91 | MAPT (0.82) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL18508908 | 0.90 | MAPT (0.81) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL28360809 | 0.89 | CAPN1 (0.85) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL16382581 | 0.89 | MAPT (0.78) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL29449851 | 0.88 | MAPT (0.79) | MAPTALDH1A1MEN1KMT2AJUN | |
| SCHEMBL79457 | 0.88 | MAPT (0.79) | MAPTALDH1A1MEN1KMT2AJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-11209421-B2 | Cytidine deaminase expression level in cancer as a new therapeutic target | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-28 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190293629-A1 | CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-23 | — | — | US | disclosed |
| WO-2011033115-A2 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-24 | — | — | WO | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | MAPT 497/4885ALDH1A1 371/4885MEN1 1363/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | MAPT 448/4885ALDH1A1 670/4885MEN1 3638/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | MAPT 497/4885ALDH1A1 371/4885MEN1 1363/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | MAPT 448/4885ALDH1A1 670/4885MEN1 3638/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPT 497/4885ALDH1A1 371/4885MEN1 1363/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | MAPT 198/4885ALDH1A1 320/4885MEN1 2595/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPT 497/4885ALDH1A1 371/4885MEN1 1363/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPT 497/4885ALDH1A1 371/4885MEN1 1363/4885 |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | TST, PDXK, TBCB | MAPT 4863/4885ALDH1A1 1763/4885MEN1 4710/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | MAPT 198/4885ALDH1A1 320/4885MEN1 2595/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | MAPT 2066/4885ALDH1A1 110/4885MEN1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.